Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » EVSC news out!! Looks good

 - UBBFriend: Email this page to someone!    
Author Topic: EVSC news out!! Looks good
falkor923
Member


Rate Member
Icon 1 posted      Profile for falkor923     Send New Private Message       Edit/Delete Post   Reply With Quote 
Make sure to look at this for today because this news looks big!!

Financial News





Press Release Source: Endovasc Inc.


Endovasc Phase II Clinical Trial Results Exceed Expectations
Thursday August 19, 8:01 am ET
Liprostin Shows Significant Improvement in Patients' Quality of Life


MONTGOMERY, Texas--(BUSINESS WIRE)--Aug. 19, 2004--Endovasc Inc. (OTCBB: EVSC - News), a drug development company that pioneers new cardiovascular and metabolic drug therapies, today announced the completion and results of the Company's Phase II clinical trial to evaluate the effects of the Liprostin(TM) in patients suffering from peripheral vascular disease (PVD), including critical limb ischemia (CLI) and intermittent claudication (leg pain). Technically, these patients were classified as Fontaine's stage IIa, IIb, or III, and were primarily over 40 years of age.
ADVERTISEMENT


The Phase II study concluded successfully with results, from the 73 patients completing the trial, showing significant improvements in both the mean walking distance and pain-free walking distance, the primary end points of trial. The three-month trial consisted of ten patient visits over twelve weeks. Baseline was determined during visits one and two. The Company is pleased to announce that the Maximum Walking Distance increased over 100% and the average Pain Free Maximum Walking Distance increased almost 200%. In addition, patient response to the trial PADWIQ standard questionnaire revealed significant day to day quality of life improvements as indicated by an increase in their overall walking distance and walking speed.

According to CEO and President, Dr. Diane Dottavio, "We witnessed a dramatic increase in walking distance and reduction in walking pain after only six treatments of Liprostin. But the most exciting outcome of the trial was that patients continued to improve, during the third month of the trial, even though they were no longer receiving the drug. This reflects highly on Liprostin' encapsulated formulation and validates our delivery method of PGE-1. Due to this unexpected and welcomed patient improvement that continued during the one month post-treatment evaluation, an extended trial may be necessary to evaluate the sustained improvement of these patients."

Peripheral Vascular Disease patients go largely undiagnosed and under-treated, and there is a great need for improvement in less invasive treatment options such as Liprostin. Peripheral vascular disease is a condition in which the arteries that carry blood throughout the body become narrowed or clogged, resulting in diminished blood flow. The most common symptoms are pain or numbness, and could result in amputation of affected limbs if the condition is left untreated. Endovasc's Liprostin is a liposome-encapsulated form of prostaglandin E-1 (PGE-1). PGE-1 is known to be a potent vasodilator and platelet inhibitor, as well as an anti-inflammatory and anti-thrombotic agent. The encapsulated formulation (Liprostin) has been shown to improve the therapeutic index of PGE-1 resulting in prolonged improvement of patients, and may positively impact many areas of treatment, such as heart attacks, occlusive disease, ischemic ulcers, critical limb salvage, claudicants, and arthritis.

The market potential of Liprostin is estimated to be in excess of 100 million dollars annually. In the United States, as many as 10 million Americans over the age of 40 have PAD and it is estimated that approximately 20% of people ages 55 and older in the United States have PAD, which represents a significant opportunity. Currently, the Company is reviewing a number of financial strategies to move Liprostin forward and into a phase III clinical trials.

About Endovasc

Endovasc, Inc., established in 1996, is an innovative drug development company with two new cardiovascular and metabolic drug therapies. Endovasc's mission is to design the delivery, and release drugs to their intended targets in an efficient and controlled manner. Endovasc's lead drug candidates include Angiogenix(TM) and Liprostin. Endovasc also has a stent coating technology, PROStent(TM), in pre-clinical trials.

For more information about Endovasc, please visit www.endovasc.com.

Safe Harbor

This news release includes statements that are not historical facts and are considered "forward-looking" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Endovascs' current views about future events. They are identified by their use of terms and phrases such as "believe," "expect," "plan," "anticipate", "possibility" and similar expressions identifying their forward-looking character. Investors should not rely on these forward-looking statements as assurances of future events, because such statements are inherently subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from the Company's expectations. The factors that may affect the outcome of such expectations include, but are not limited to factors detailed from time to time in the Company's filings with the Securities and Exchange Commission.

--------------------------------------------------------------------------------
Contact:
Investor Relations:
FOCUS Partners LLC
David Zazoff, 212-752-9445


[This message has been edited by falkor923 (edited August 19, 2004).]


Posts: 55 | From: new castle, delaware | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
Garfield1981
Member


Rate Member
Icon 1 posted      Profile for Garfield1981     Send New Private Message       Edit/Delete Post   Reply With Quote 
I am in!!
Posts: 233 | Registered: Jul 2004  |  IP: Logged | Report this post to a Moderator
Garfield1981
Member


Rate Member
Icon 1 posted      Profile for Garfield1981     Send New Private Message       Edit/Delete Post   Reply With Quote 
Yahoo group in action, join the ride before the run.
Posts: 233 | Registered: Jul 2004  |  IP: Logged | Report this post to a Moderator
FurrySound
Member


Member Rated:
4
Icon 1 posted      Profile for FurrySound     Send New Private Message       Edit/Delete Post   Reply With Quote 
That interesting news... good sign they are on the right track.

------------------
FurrySound
-DD-GLTA-Unless I've quoted a source, I know not what I speak of.


Posts: 2170 | From: Pennsylvania, USA | Registered: Mar 2004  |  IP: Logged | Report this post to a Moderator
ThePennyKing
Member


Rate Member
Icon 1 posted      Profile for ThePennyKing     Send New Private Message       Edit/Delete Post   Reply With Quote 
Awesome news! Good things happening for this company, and pps only gonna soar from these low levels. PRIME opportunity to get in.
Posts: 71 | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
Garfield1981
Member


Rate Member
Icon 1 posted      Profile for Garfield1981     Send New Private Message       Edit/Delete Post   Reply With Quote 
BID and ASK both up, about to move, Yeah!!!
Posts: 233 | Registered: Jul 2004  |  IP: Logged | Report this post to a Moderator
justmeumm
New Member


Rate Member
Icon 1 posted      Profile for justmeumm     Send New Private Message       Edit/Delete Post   Reply With Quote 
Great news ! Count me in !!

quote:
Originally posted by falkor923:
Make sure to look at this for today because this news looks big!!

Financial News





Press Release Source: Endovasc Inc.


Endovasc Phase II Clinical Trial Results Exceed Expectations
Thursday August 19, 8:01 am ET
Liprostin Shows Significant Improvement in Patients' Quality of Life


MONTGOMERY, Texas--(BUSINESS WIRE)--Aug. 19, 2004--Endovasc Inc. (OTCBB: EVSC - News), a drug development company that pioneers new cardiovascular and metabolic drug therapies, today announced the completion and results of the Company's Phase II clinical trial to evaluate the effects of the Liprostin(TM) in patients suffering from peripheral vascular disease (PVD), including critical limb ischemia (CLI) and intermittent claudication (leg pain). Technically, these patients were classified as Fontaine's stage IIa, IIb, or III, and were primarily over 40 years of age.
ADVERTISEMENT


The Phase II study concluded successfully with results, from the 73 patients completing the trial, showing significant improvements in both the mean walking distance and pain-free walking distance, the primary end points of trial. The three-month trial consisted of ten patient visits over twelve weeks. Baseline was determined during visits one and two. The Company is pleased to announce that the Maximum Walking Distance increased over 100% and the average Pain Free Maximum Walking Distance increased almost 200%. In addition, patient response to the trial PADWIQ standard questionnaire revealed significant day to day quality of life improvements as indicated by an increase in their overall walking distance and walking speed.

According to CEO and President, Dr. Diane Dottavio, "We witnessed a dramatic increase in walking distance and reduction in walking pain after only six treatments of Liprostin. But the most exciting outcome of the trial was that patients continued to improve, during the third month of the trial, even though they were no longer receiving the drug. This reflects highly on Liprostin' encapsulated formulation and validates our delivery method of PGE-1. Due to this unexpected and welcomed patient improvement that continued during the one month post-treatment evaluation, an extended trial may be necessary to evaluate the sustained improvement of these patients."

Peripheral Vascular Disease patients go largely undiagnosed and under-treated, and there is a great need for improvement in less invasive treatment options such as Liprostin. Peripheral vascular disease is a condition in which the arteries that carry blood throughout the body become narrowed or clogged, resulting in diminished blood flow. The most common symptoms are pain or numbness, and could result in amputation of affected limbs if the condition is left untreated. Endovasc's Liprostin is a liposome-encapsulated form of prostaglandin E-1 (PGE-1). PGE-1 is known to be a potent vasodilator and platelet inhibitor, as well as an anti-inflammatory and anti-thrombotic agent. The encapsulated formulation (Liprostin) has been shown to improve the therapeutic index of PGE-1 resulting in prolonged improvement of patients, and may positively impact many areas of treatment, such as heart attacks, occlusive disease, ischemic ulcers, critical limb salvage, claudicants, and arthritis.

The market potential of Liprostin is estimated to be in excess of 100 million dollars annually. In the United States, as many as 10 million Americans over the age of 40 have PAD and it is estimated that approximately 20% of people ages 55 and older in the United States have PAD, which represents a significant opportunity. Currently, the Company is reviewing a number of financial strategies to move Liprostin forward and into a phase III clinical trials.

About Endovasc

Endovasc, Inc., established in 1996, is an innovative drug development company with two new cardiovascular and metabolic drug therapies. Endovasc's mission is to design the delivery, and release drugs to their intended targets in an efficient and controlled manner. Endovasc's lead drug candidates include Angiogenix(TM) and Liprostin. Endovasc also has a stent coating technology, PROStent(TM), in pre-clinical trials.

For more information about Endovasc, please visit www.endovasc.com.

Safe Harbor

This news release includes statements that are not historical facts and are considered "forward-looking" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Endovascs' current views about future events. They are identified by their use of terms and phrases such as "believe," "expect," "plan," "anticipate", "possibility" and similar expressions identifying their forward-looking character. Investors should not rely on these forward-looking statements as assurances of future events, because such statements are inherently subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from the Company's expectations. The factors that may affect the outcome of such expectations include, but are not limited to factors detailed from time to time in the Company's filings with the Securities and Exchange Commission.



Posts: 4 | From: Genoa, WI, United States | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
Garfield1981
Member


Rate Member
Icon 1 posted      Profile for Garfield1981     Send New Private Message       Edit/Delete Post   Reply With Quote 
Another news will come soon.
BID building up, ASK is moving up too.
Get in now. Target .25 short term.

Posts: 233 | Registered: Jul 2004  |  IP: Logged | Report this post to a Moderator
Garfield1981
Member


Rate Member
Icon 1 posted      Profile for Garfield1981     Send New Private Message       Edit/Delete Post   Reply With Quote 
BID and ASK up again.
Get in before the bell.
Will open higher tomorrow morning.
News will be here soon.

Posts: 233 | Registered: Jul 2004  |  IP: Logged | Report this post to a Moderator
level2iscool2004
Member


Member Rated:
5
Icon 1 posted      Profile for level2iscool2004     Send New Private Message       Edit/Delete Post   Reply With Quote 
.25 target next week also AMTK will have news on monday so add some of it at .065 while its ask is still under .07 EVSC rumored to have more news on tuesday btw
Posts: 129 | From: united states | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
Ka-Ching
Member


Member Rated:
4
Icon 1 posted      Profile for Ka-Ching         Edit/Delete Post   Reply With Quote 
I'm holding in anticipation of this weeks' news. Love this pharm. company. Doing good things, and have more in the pipeline.
Love this excerpt from latest NEWS! :

"The market potential of Liprostin is estimated to be in excess of 100 million dollars annually. In the United States, as many as 10 million Americans over the age of 40 have PAD and it is estimated that approximately 20% of people ages 55 and older in the United States have PAD, which represents a significant opportunity."

Much potential here folks, short-term and long.


Posts: 323 | Registered: May 2004  |  IP: Logged | Report this post to a Moderator
Jeremy
Member


Rate Member
Icon 1 posted      Profile for Jeremy     Send New Private Message       Edit/Delete Post   Reply With Quote 
I got in a few days ago, very low float, promising numbers, and some good news recently.
Posts: 1051 | From: Michigan | Registered: Sep 2003  |  IP: Logged | Report this post to a Moderator
falkor923
Member


Rate Member
Icon 1 posted      Profile for falkor923     Send New Private Message       Edit/Delete Post   Reply With Quote 
When news came out on the 19th it opened at .12 and closed at .14 pps.
Now there are more grumblimgs of news for the 23rd. Wonder what it's gonna do? keep an eye on it.

Posts: 55 | From: new castle, delaware | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
falkor923
Member


Rate Member
Icon 1 posted      Profile for falkor923     Send New Private Message       Edit/Delete Post   Reply With Quote 
news out....again.
Posts: 55 | From: new castle, delaware | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
ThePennyKing
Member


Rate Member
Icon 1 posted      Profile for ThePennyKing     Send New Private Message       Edit/Delete Post   Reply With Quote 
As we predicted, MORE good news out for this company! Nice chart on EVSC...good steady buying, as everyone sees this companys' potential. Nice bounce off of 52wk lows, just beginning of uptrend here.
Posts: 71 | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
ThePennyKing
Member


Rate Member
Icon 1 posted      Profile for ThePennyKing     Send New Private Message       Edit/Delete Post   Reply With Quote 
As we predicted, MORE good news out for this company! Nice chart on EVSC...good steady buying, as everyone sees this companys' potential. Nice bounce off of 52wk lows, just beginning of uptrend here.
Posts: 71 | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2019 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share